Sharad Ghamande

A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

Bradley J. Monk, Christine Parkinson, Myong Cheol Lim et al. · Journal of Clinical Oncology · 2022 · 346 citations · Full text

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Ana Oaknin, Lucy Gilbert, Anna V. Tinker et al. · Journal for ImmunoTherapy of Cancer · 2022 · 300 citations · Full text

PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer

R. Wendel Naumann, Robert L. Coleman, Robert A. Burger et al. · Journal of Clinical Oncology · 2013 · 227 citations

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Ursula A. Matulonis, Ignace Vergote, Floor Backes et al. · Gynecologic Oncology · 2014 · 118 citations

Tumoral Pathology, Medicine, Gynecology +9

Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial

Rodney P. Rocconi, Elizabeth A. Grosen, Sharad Ghamande et al. · The Lancet Oncology · 2020 · 112 citations

Medicine, Immunology, Gynecology +6